Imaging adipose tissue browning using the TSP0-18kDa tracer [18F]FEPPA

S.V. Hartimath 1, S. Khanapur 1, R. Boominathan 1, L. Jiang 1, P. Cheng 1, F.F. Yong 1, P.W. Tan 1, E.G. Robins 1, 2, J.L. Goggi 1, 6

ABSTRACT

Objectives: The browning of white adipose tissue (WAT) into beige has been proposed as a strategy to enhance energy expenditure to combat the growing epidemic of obesity. Research into browning strategies are hampered by the lack of sensitive, translatable, imaging tools capable of detecting beige fat mass non-invasively. [18F]FDG is able to detect activated beige fat but provides little information on unstimulated beige fat mass. We have assessed the use of [18F]FEPPA, a tracer for the TSP0-18kDa found on the outer mitochondrial membrane, as an alternative imaging agent capable of detecting unstimulated brown fat (BAT) and beige fat.

Methods: Female Balb/c mice (n = 5) were treated for 7 days with the β3 adrenergic agonist CL-316,243 to induce the browning of inguinal WAT (beige fat). Animals were imaged longitudinally with [18F]FDG and [18F]FEPPA and uptake in interscapular BAT and inguinal WAT assessed. The browning of inguinal WAT was confirmed using H&E and immunohistochemical detection of UCP-1 and TSPO.

Results: Repeated dosing with β3-adrenergic agonist CL-316,243 caused a significant increase in [18F]FDG uptake in both interscapular BAT and inguinal WAT associated with the increased metabolic activity of brown and beige adipocytes respectively. [18F]FEPPA uptake was likewise increased in inguinal WAT but showed no increase in BAT uptake due to stimulation over the same time course. Furthermore, inguinal WAT uptake was unaffected by pharmacological blockade, indicating that [18F]FEPPA uptake is associated with the expression of mitochondria in BAT and beige adipocytes and independent of activation.

Conclusion: These data show that [18F]FEPPA can detect BAT and newly formed beige fat under non-stimulated, thermoneutral conditions and that uptake after stimulation is linked to mitochondrial expression as opposed to activation.

Key words: Brown fat; Beige; β3-adrenergic receptor; FDG; TSP0-18kDa; PET imaging

1. INTRODUCTION

Metabolically active brown adipose tissue (BAT) plays a significant role in metabolism and energy regulation [1–3]. While white adipose tissue (WAT) is responsible for energy storage, BAT is responsible for dissipating energy through the action of the uncoupling protein-1 (UCP1). In adults, increased BAT mass has been linked to lower body mass index [10,11]. The browning of inguinal WAT was confirmed using H&E and immunohistochemical detection of UCP-1 and TSPO.

Material and Methods

1. INTRODUCTION

Metabolically active brown adipose tissue (BAT) plays a significant role in metabolism and energy regulation [1–3]. While white adipose tissue (WAT) is responsible for energy storage, BAT is responsible for dissipating energy through the action of the uncoupling protein-1 (UCP1). In adults, increased BAT mass has been linked to lower body mass index [10,11]. The browning of inguinal WAT was confirmed using H&E and immunohistochemical detection of UCP-1 and TSPO.

Material and Methods

1. INTRODUCTION

Metabolically active brown adipose tissue (BAT) plays a significant role in metabolism and energy regulation [1–3]. While white adipose tissue (WAT) is responsible for energy storage, BAT is responsible for dissipating energy through the action of the uncoupling protein-1 (UCP1). In adults, increased BAT mass has been linked to lower body mass index [10,11]. The browning of inguinal WAT was confirmed using H&E and immunohistochemical detection of UCP-1 and TSPO.

Material and Methods

1. INTRODUCTION

Metabolically active brown adipose tissue (BAT) plays a significant role in metabolism and energy regulation [1–3]. While white adipose tissue (WAT) is responsible for energy storage, BAT is responsible for dissipating energy through the action of the uncoupling protein-1 (UCP1). In adults, increased BAT mass has been linked to lower body mass index [10,11]. The browning of inguinal WAT was confirmed using H&E and immunohistochemical detection of UCP-1 and TSPO.

Material and Methods

1. INTRODUCTION

Metabolically active brown adipose tissue (BAT) plays a significant role in metabolism and energy regulation [1–3]. While white adipose tissue (WAT) is responsible for energy storage, BAT is responsible for dissipating energy through the action of the uncoupling protein-1 (UCP1). In adults, increased BAT mass has been linked to lower body mass index [10,11]. The browning of inguinal WAT was confirmed using H&E and immunohistochemical detection of UCP-1 and TSPO.

Material and Methods

1. INTRODUCTION

Metabolically active brown adipose tissue (BAT) plays a significant role in metabolism and energy regulation [1–3]. While white adipose tissue (WAT) is responsible for energy storage, BAT is responsible for dissipating energy through the action of the uncoupling protein-1 (UCP1). In adults, increased BAT mass has been linked to lower body mass index [10,11]. The browning of inguinal WAT was confirmed using H&E and immunohistochemical detection of UCP-1 and TSPO.

Material and Methods

1. INTRODUCTION

Metabolically active brown adipose tissue (BAT) plays a significant role in metabolism and energy regulation [1–3]. While white adipose tissue (WAT) is responsible for energy storage, BAT is responsible for dissipating energy through the action of the uncoupling protein-1 (UCP1). In adults, increased BAT mass has been linked to lower body mass index [10,11]. The browning of inguinal WAT was confirmed using H&E and immunohistochemical detection of UCP-1 and TSPO.

Material and Methods

1. INTRODUCTION

Metabolically active brown adipose tissue (BAT) plays a significant role in metabolism and energy regulation [1–3]. While white adipose tissue (WAT) is responsible for energy storage, BAT is responsible for dissipating energy through the action of the uncoupling protein-1 (UCP1). In adults, increased BAT mass has been linked to lower body mass index [10,11]. The browning of inguinal WAT was confirmed using H&E and immunohistochemical detection of UCP-1 and TSPO.

Material and Methods

1. INTRODUCTION

Metabolically active brown adipose tissue (BAT) plays a significant role in metabolism and energy regulation [1–3]. While white adipose tissue (WAT) is responsible for energy storage, BAT is responsible for dissipating energy through the action of the uncoupling protein-1 (UCP1). In adults, increased BAT mass has been linked to lower body mass index [10,11]. The browning of inguinal WAT was confirmed using H&E and immunohistochemical detection of UCP-1 and TSPO.

Material and Methods

1. INTRODUCTION

Metabolically active brown adipose tissue (BAT) plays a significant role in metabolism and energy regulation [1–3]. While white adipose tissue (WAT) is responsible for energy storage, BAT is responsible for dissipating energy through the action of the uncoupling protein-1 (UCP1). In adults, increased BAT mass has been linked to lower body mass index [10,11]. The browning of inguinal WAT was confirmed using H&E and immunohistochemical detection of UCP-1 and TSPO.

Material and Methods

1. INTRODUCTION

Metabolically active brown adipose tissue (BAT) plays a significant role in metabolism and energy regulation [1–3]. While white adipose tissue (WAT) is responsible for energy storage, BAT is responsible for dissipating energy through the action of the uncoupling protein-1 (UCP1). In adults, increased BAT mass has been linked to lower body mass index [10,11]. The browning of inguinal WAT was confirmed using H&E and immunohistochemical detection of UCP-1 and TSPO.
tracer $[^{11}]$C-PBR28 has already been shown to identify BAT mass clinically [18]. The current study, however, is the first to attempt to use a TSP0 tracer to detect the development of new beige fat deposits in WAT after β3AR agonist stimulation.

2. MATERIALS AND METHODS

No-carrier-added aqueous $[^{18}]$F fluoride ion was produced via the $[^{18}]$O(p,n)$[^{18}]$F nuclear reaction (GE PETtrace 860 cyclotron). The compounds 2- (N-(4-phenoxypropin-3-yl)acetamidomethyl(phenoxycarbonyl)-4-ethyl-4-methylenbenzenesulfonate (FEPPA precursor, catalogue number 1654) and N-(2-(2-Fluoroethoxy)benzyl)-N-(4-phenoxypropin-3-yl)acetamide (FEPPA reference standard, catalogue number 1655) were purchased from ABX GmbH, Germany. Acetonitrile (99.8%), anhydrous potassium carbonate (99.99%), 4,7,13,16,21,24-hexaoxa-1,10-diazabicyclo[8.8.8]hexacosane (Kryptofix® 222, 98%), phosphoric acid 85 wt% in H2O (99.99%), and sodium bicarbonate (≥99.7%) were procured from Sigma-Aldrich Pte Ltd. HPLC-grade acetonitrile and Millex GV 0.22 μm filters were purchased from Merck Pte. Ltd. and 0.9% wt saline solution was purchased from Braun Medical Industries and used as supplied.

All reactions were carried out in closed Thermo Scientific™ conical reacti-vial™ (5 ml capacity). Sep-Pak® light (46 mg) Accell™ plus QMA carbonate was purchased from Waters Corporation and pre-conditioned with 10 ml deionized water (Elga Purelab Flex3, 0.9 MΩ, 1587 MBq in ca. 2.5 ml) was trapped on a preconditioned Sep-Pak® light (46 mg) Accell™ plus QMA carbonate (Waters). The trapped $[^{18}]$F fluoride anion was eluted into the reaction vial using 1 ml of a 96: 4 (w/v) acetonitrile: water mixture containing K2CO3 (3 mg, 21.7 μmol) and Kryptofix 222 (14.5 mg, 38.5 μmol). The [K(K222)]$[^{18}]$F complex was azeotropically dried under a stream of nitrogen gas (250 ml/min) at 90 °C with the addition of 1 × 0.5 ml anhydrous acetonitrile. After cooling, a solution of the tosyl-precursor (5 mg, 9.4 μmol) in anhydrous acetonitrile (0.7 ml) was added before the reaction vial was sealed and heated at 90 °C for a further 10 min. After cooling to room temperature, the crude reaction mixture was diluted with 3 ml HPLC mobile phase (30/70 v/v ethanol:0.1% phosphoric acid in water) and subjected to purification by isotropic semi-preparative radio-HPLC (Nucleodur pyramid C18, 5 μm, 110 A, 250 × 10 mm; 30/70 v/v ethanol: 0.1% phosphoric acid in water; 5 ml/min, λ = 254 nm). The $[^{18}]$F FEPPA fraction was isolated with a retention time of between 13.5 and 13.7 min, neutralized with 10% sodium bicarbonate solution (1 ml) and diluted to 10 ml with 0.9% w/v saline before filtration through 0.22 μm Millex GV filter to afford the final product. The $[^{18}]$F FEPPA was prepared with a non-decay corrected radiochemical yield of 40 ± 7% within 50–60 min (n = 12) from aqueous $[^{18}]$F fluoride. The radiochemical purity was greater than 99% and molar activity was 114 ± 54 GBq/μmol at the end of the synthesis. The radiochemical identity of the $[^{18}]$F FEPPA was confirmed by co-elution of the product with an authentic sample of $[^{18}]$F FEPPA using analytical radio-HPLC (Shim-pack GIST C18, 5 μ, 100 Å, 250 mm × 4.6 mm column, water: acetonitrile gradient elution 0.01–0.20 min 10% acetonitrile, 0.20–6.00 min 10–95% acetonitrile, 6.00–10.00 min 95–10% acetonitrile, flow rate of 2 ml/min, λ = 254 nm). The retention time of authentic $[^{18}]$F FEPPA and $[^{18}]$F FEPPA was 6 min. The solution stability of formulated $[^{18}]$F FEPPA was assessed over 7.5 h at room temperature (n = 2) during which time no change in radiochemical purity was observed.

2.2. Animal procedures

Animal procedures were carried out in accordance with the Institutional Animal Care and Use Committee Singapore. BALB/c mice aged 6–8 weeks were purchased from In Vivos Singapore, kept at room temperature with a 12-hour light–dark cycle and had free access to food and water. Saline or β3-adrenergic receptor agonist CL-316,243 compound (1 mg/kg) was administered intraperitoneally daily for 7 days. β3-adrenergic receptor antagonist L-748,328 (1 mg/kg) was administered 1 h prior to imaging on Day 7 to determine basal binding.

2.3. PET-CT and MR imaging

The animals were imaged longitudinally 0, 1, 4, and 7 days after initiation of treatment using the Siemens Inveon PET-CT and the Mediso nanoscan 3T MR system using a modified version of the methodology described by Wang et al. [20]. Briefly, animals were imaged one hour after dosing with either CL-316,243 or vehicle, anaesthetized using inhalational iso-flurane anesthesia (maintained at 1.5% alveolar concentration) and injected with either $[^{18}]$F FDG or $[^{18}]$F FEPPA (~10 MBq per animal) via the lateral tail vein. They were maintained heated and anaesthetized throughout the procedure. Static PET acquisitions were performed at 60–80 min post-injection and CT and T2 weighted fast spin echo MR scans were used to delineate fat deposits (TR 3843 ms, TE 87.5 ms, matrix size 256 × 256, 50.0 mm FOV, 1.0 mm slice thickness with no slice gap acquisition time 9 min).

Animals were monitored for maintenance of body temperature and respiration rate during imaging studies using the Biovet physiological monitoring system. Post-analysis of reconstructed calibrated images were performed with FIJ and Amide software (version 10.3 Source-forge). Uptake of radioactivity in the fat depots was determined by the placement of a volume of interest (VOI) around the interscapular BAT and inguinal WAT regions as delineated by CT and MR imaging. A VOI was also placed in the quadriceps muscle to provide reference tissue values.

2.4. Histology

On day 7, the inguinal fat tissues were dissected and fixed with 10% formalin, embedded in paraffin and sectioned. Sections were stained with hematoxylin and eosin (H&E) or were probed with an antibody for UCP1 (1:100, ab23841, Abcam) or TSPO-18kDa (1:100, ab109497, Abcam).

2.5. Statistical analysis

A two-way ANOVA with multiple Bonferroni post-test was performed using GraphPad Prism version 8.0.0 for Windows, GraphPad Software, San Diego, California USA, www.graphpad.com, p < 0.05 was considered statistically significant. Data are expressed as mean and error bars are expressed as ± SD.
3. RESULTS

3.1. Quantification of inguinal adipose browning with [18F]FDG and [18F]FEPPA PET imaging

PET imaging combined with CT was performed on days 0, 1, 4, and 7 post dosing with CL-316,243. As seen in Figure 1B, the retention of both [18F]FDG and [18F]FEPPA in inguinal WAT was significantly increased after subchronic treatment with CL-316,243. On Day 1, CL-316,243 treatment had no significant effect on retention of [18F]FDG (1.6 ± 0.6% ID/g) compared to vehicle treatment (1.7 ± 0.6% ID/g) nor on the retention of [18F]FEPPA (3.7 ± 0.8% ID/g) compared to vehicle (2.8 ± 1.2% ID/g). By Day 4, the retention of [18F]FDG was significantly increased in the CL-316,243 treated inguinal WAT (3.5 ± 1.5% ID/g compared to 1.8 ± 0.5% ID/g in the vehicle *p = 0.02). Likewise, the retention of [18F]FEPPA was significantly increased in the CL-316,243 treated inguinal WAT (4.9 ± 1.0% ID/g compared to 2.9 ± 0.5% ID/g in the vehicle ***p = 0.004) after 4 days of treatment. Radiotracer uptake was further increased in inguinal WAT by Day 7 in the CL-316,243 treated inguinal WAT for both [18F]FDG (4.4 ± 0.8% ID/g compared to 1.5 ± 0.4% ID/g in the vehicle ****p = 0.0001) and [18F]FEPPA (7.0 ± 1.3% ID/g compared to 2.5 ± 0.5% ID/g in the vehicle ****p = 0.00009). Pretreatment with the β3AR antagonist L-748,328 had no significant effect on [18F]FEPPA uptake in inguinal WAT on Day 7 (Figure 1D, 6.43 ± 0.63% ID/g).

3.2. Interscapular brown fat imaging with [18F]FDG and [18F]FEPPA

As seen in Figure 1C, while the retention of [18F]FDG in interscapular brown fat significantly increased with CL-316,243 treatment, the uptake of [18F]FEPPA remained unchanged. On Day 1, CL-316,243 treatment had no significant effect on retention of [18F]FDG (5.7 ± 2.4% ID/g) compared to vehicle treatment (4.4 ± 0.7% ID/g). By Day 4, the retention of [18F]FDG was significantly increased in the CL-316,243 treated BAT (7.6 ± 1.6% ID/g compared to 4.0 ± 0.7% ID/g in the vehicle *p = 0.0194) and further increased by Day 7 (16.8 ± 2.1% ID/g compared to 4.2 ± 0.4% ID/g in the vehicle ***p = 0.0004). In contrast, [18F]FEPPA retention was unchanged at any of the days studied post stimulation (Day 1; 56.3 ± 17.0% ID/g in CL-treated compared to vehicle 57.3 ± 15.6% ID/g, Day 4; 56.3 ± 17.0% ID/g in CL-treated compared to vehicle 57.3 ± 8.3% ID/g and Day 7; 60.6 ± 9.9% ID/g in CL-
treated compared to vehicle 61.0 ± 5.6% ID/g. Pretreatment with the \(\beta_3\)AR antagonist L-748,328 to block CL-316,243 stimulation had no significant effect on \([^{18}F]FEPPA\) uptake in interscapular BAT on Day 7 (57.5 ± 4.3% ID/g).

### 3.3. Histology

Histological and immunohistochemical assessment of WAT was performed after 7 days of stimulation. H&E staining clearly shows a significant increase in the presence of multilocular fat cells indicative of brown adipocyte conversion after CL-316,243 treatment compared to vehicle (Figure 1E upper panel). These findings are corroborated by immunohistochemical staining for UCP-1 (Figure 1E middle panel). IHC shows a clear increase in TSPO-18kDa expression in areas displaying staining of UCP-1 expression (Figure 1E lower panel). PET imaging provides a uniquely sensitive method for non-invasive assessment of browning. Currently only PET imaging provides a uniquely sensitive method for non-invasive staining of UCP-1 expression (Figure 1E lower panel).

Recent attempts to induce beige fat necessitate the development of sensitive and specific, translatable, imaging methodologies to accurately detect beige fat mass in vivo. Molecular imaging probes have been assessed for their ability to quantitate beige fat across the spectrum of imaging with varying degrees of success. Optical imaging techniques including endogenous contrast and near infrared dyes have proven effective in preclinical models but clinical translation is limited [9,23–25]. Clinical techniques such as MRI, skin temperature measurements, near-infrared spectroscopy, and contrast-enhanced ultrasound show the ability to accurately determine BAT mass or metabolic activity but are too insensitive to reliably detect de novo formation of beige fat [26,27]. PET imaging provides a uniquely sensitive method for non-invasive assessment of browning. Currently only \([^{18}F]FDG\) uptake in stimulated beige fat has been well documented. \([^{18}F]FDG\) uptake is linked to hexokinase 2 and UCP-1 (uncoupling protein 1) activity [9,28] providing information on the metabolic activity of the beige adipocytes but little information on the number of beige adipocytes induced by stimulation. Beige adipocyte biogenesis in WAT is induced in response to multiple external stimuli including chronic cold, exercise and \(\beta_3\)AR agonists. These stimuli induce transdifferentiation of white adipocytes into beige adipocytes through a process involving the activation of PPAR\(\gamma\) (peroxisome proliferator-activated receptor-\(\gamma\)) [29] and the PRDM16 (PRD1 domain containing protein 16) pathway [28]. Typically this conversion has been confirmed by measuring standard markers of brown adipocytes including UCP1 and mitochondrial expression. Beige adipocytes possess abundant mitochondria which express TSPO providing ample binding sites for \([^{18}F]FEPPA\) and the surrounding white adipocytes have few mitochondria [13,15], minimizing background uptake. Furthermore, \([^{18}F]FEPPA\) measurement of mitochondrial TSPO expression is independent of activation, as shown by the \(\beta_3\)AR antagonist L-748,328 which had no effect on \([^{18}F]FEPPA\) uptake in beige fat or BAT. TSPO radiopharmaceuticals seem well suited to detect beige fat mass independent of stimulation, however, this study has several limitations; firstly \([^{18}F]FEPPA\) uptake has not been assessed in completely unstimulated beige fat as expression is transient, reverting to the white phenotype within days of withdrawal of stimulation [30]. Secondly, we are unable to quantify the proportion of \([^{18}F]FEPPA\) uptake that may be due to non-specific binding such as the increased vascularity associated with beige fat or infiltration of macrophages which express particularly high levels of TSPO. Also \(\beta_3\)AR stimulation is a potent inducer of beige fat, useful in preclinical models, however, clinical approaches to induce beige fat, such as cold acclimation and exercise are less potent raising the question of how sensitive a measure of unstimulated beige fat might be in humans. It is not currently understood how many white adipocytes can undergo transdifferentiation to beige adipocytes, previous studies using cold stimulation in rodents have suggested up to 50% but this may be different in humans and dependent on adipocyte population or microenvironment [29,31]. Thus further work may be necessary to evaluate \([^{18}F]FEPPA\) for clinical use under these paradigms.

Overall, these data suggest that the TSPO tracer \([^{18}F]FEPPA\) may be useful for detecting unstimulated beige adipocytes. As \([^{18}F]FEPPA\) has been used to assess neuroinflammation in patients [32–34], it could potentially be repurposed to identify beige fat clinically at thermo-neutral conditions.

### ACKNOWLEDGMENTS

This work was supported by funding from the Singapore Bioimaging Consortium (SBIC), A*STAR, Singapore.

### CONFLICT OF INTEREST

None.

### APPENDIX A. SUPPLEMENTARY DATA

Supplementary data to this article can be found online at https://doi.org/10.1016/j.molmet.2019.05.003.

### REFERENCES

[1] Bartelt, A., Bruns, O.T., Reimer, R., Hohenberg, H., Ilbich, H., Pelschus, K., et al., 2011. Brown adipose tissue activity controls triglyceride clearance. Nature Medicine 17(2):200–205, https://doi.org/10.1038/nm.2297, PubMed PMID: 21258337.

[2] Gunawardana, S.C., 2012. Therapeutic value of brown adipose tissue: Correcting metabolic disease through generating healthy fat. Adipocyte 1(4):250–255, https://doi.org/10.4161/adip.21042, PubMed PMID: 23700541; PubMed Central PMCID: PMC3609108.

[3] Gunawardana, S.C., Piston, D.W., 2012. Reversal of type 1 diabetes in mice by brown adipose tissue transplant. Diabetes 61(3):674–682, https://doi.org/10.2337/db11-0510, PubMed PMID: 22315305; PubMed Central PMCID: PMC3262804.

[4] Nedergraad, J., Bengtsson, T., Cannon, B., 2007. Unexpected evidence for active brown adipose tissue in adult humans. American Journal of Physiology Endocrinology and Metabolism 293(2):E444–E452, https://doi.org/10.1152/ajpendo.00691.2006, PubMed PMID: 17473055.

[5] Symonds, M.E., Aldiss, P., Pope, M., Budge, H., 2018. Recent advances in our understanding of brown and beige adipose tissue: the good fat that keeps you healthy. F1000Research 7. https://doi.org/10.12688/f1000research.14585.1, PubMed PMID: 30079236; PubMed Central PMCID: PMC6058473.

[6] Bhanu Prakash, K.N., Verma, S.K., Yaligar, J., Goggi, J., Gopalan, V., Lee, S.S., et al., 2016. Segmentation and characterization of interscapular brown adipose tissue in rats by multi-parametric magnetic resonance imaging. MAGMA 29(2):277–286, https://doi.org/10.1007/s10334-015-0514-3, PubMed PMID: 26747282.

[7] Hu, H.H., 2015. Magnetic resonance of brown adipose tissue: a review of current techniques. Critical Reviews in Biomedical Engineering 43(2–3):161–181, https://doi.org/10.1615/CritRevBiomedEng.2015014377, PubMed PMID: 27278740.
Brief Communication

[8] Zhang, F., Hao, G., Shao, M., Nham, K., An, Y., Wang, Q., et al., 2018. An adipose tissue atlas: an image-guided identification of human-like BAT and beige deposits in rodents. Cell Metabolism 27(1):252–262.e3. https://doi.org/10.1016/j.cmet.2017.12.004, PubMed PMID: 29320705; PubMed Central PMCID: PMC5784189.

[9] Chan, X.H.D., Balasundaram, G., Atta, A.B.E., Goggi, J.L., Ramasamy, B., Han, W., et al., 2018. Multimodal imaging approach to monitor browning of adipose tissue in vivo. Journal of Lipid Research 59(6):1071–1078. https://doi.org/10.1194/jlr.R083410, PubMed PMID: 29654114; PubMed Central PMCID: PMC5983400.

[10] Eriksson, G., Mikkola, K., Espes, D., Tuominen, L., Virtanen, K., Forsback, S., et al., 2015. The cannabinoid receptor-1 is an imaging biomarker of brown adipose tissue. Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine 56(12):1937–1941. https://doi.org/10.2967/jnumed.115.156622, PubMed PMID: 26359260.

[11] Hwang, J.J., Yeckel, C.W., Galiezet, J.D., Aguiar, R.B., Ersahin, D., Gao, H., et al., 2015. Imaging human brown adipose tissue under room temperature conditions with [(11)C]-MRB, a selective noradrenaline transporter PET ligand. Metabolism: Clinical and Experimental 64(6):747–755. https://doi.org/10.1016/j.metabol.2015.03.001, PubMed PMID: 25798999; PubMed Central PMCID: PMC4408242.

[12] Lin, S.F., Fan, X., Yeckel, C.W., Weinzimer, D., Mulnix, T., Galiezet, J.D., et al., 2012. Ex vivo and in vivo evaluation of the noradrenaline transporter ligand [(11)C]MBIB for brown adipose tissue imaging. Nuclear Medicine and Biology 39(7):1081–1086. https://doi.org/10.1016/j.nimb.2012.04.005, PubMed PMID: 22995487; PubMed Central PMCID: PMC4067762.

[13] Madar, I., Isoda, T., Finley, P., Angle, J., Wahl, R.L., 2011. 18F-PBR28. Molecular Imaging and Biology: MIB: the Of...